Legal Compliance Index

Legal Compliance Ranking of Drugs Approved By the FDA in 20121

Ranking of new drugs according to their compliance with transparency disclosure requirements under the Food and Drug Administration Amendments Acts (FDAAA).

legal-median-results

 

 

Drug2 Company Indication Trials Subject to FDAAA Timely Registration Timely Reporting FDAAA Compliance
Sirturo Janssen (J&J) Tuberculosis 2 100% 100% 100%
MenHibrix GSK Meningitis Vaccine, Children 3 100% 100% 100%
Bosulif Pfizer Leukemia 2 100% 100% 100%
Xeljanz Pfizer Rheumatoid Arthritis 11 100% 100% 100%
Stribild Gilead HIV 3 100% 100% 100%
Inlyta Pfizer Renal Cell Carcinoma 7 100% 86% 86%
Zaltrap Sanofi Colorectal Cancer 9 100% 78% 78%
Aubagio Sanofi Multiple Sclerosis 7 86%  71% 71%
Eliquis Eliquis BMS 6 83% 33% 33%
Zioptan Merck/Santen Eye-pressure, Plaucoma 7 29% 14% 14%
Erivedge Genentech/ Roche Basal Cell Carcinoma 3 100% 0% 0%
Signifor Novartis Cushing’s Disease 2 100% 0% 0%
Perjeta Genentech/ Roche Breast Cancer 2 50% 0% 0%
Stivarga Bayer Colorectal Cancer 2 100% 0% 0%
Elelyso Pfizer/Protalix Gaucher Disease 3 100% 0% 0%

 


Footnotes

1. To learn more about our methods, data sources, and analysis, please see our in-depth publication in BMJ Open.  Our data is all publicly available at Drugs@FDA, www.clinicaltrials.gov, and through PubMed and Google Scholar searches.
2. See Appendix for a list of the active ingredients for each of our analyzed drugs.